8/9 Predictors and Mechanisms of Conversion to Psychosis

8/9 转变为精神病的预测因素和机制

基本信息

  • 批准号:
    9303457
  • 负责人:
  • 金额:
    $ 38.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Schizophrenia and other psychotic disorders are serious and debilitating mental illnesses that incur substantial suffering for patients and major challenges to our health care system. The clinical high-risk (CHR) prodromal phase is the period prior to the onset of psychosis when clinical symptoms gradually emerge and function declines. The presence of a CHR syndrome in young adults is associated with heightened risk (~30%) for the later development of psychosis. The North American Prodrome Longitudinal Study (NAPLS) and other CHR studies have made substantial progress towards predicting psychosis, and in showing an accelerated reduction in prefrontal cortex (PFC) gray matter (GM) density in CHR converters from pre- to post-psychosis onset, but the mechanisms driving conversion remain elusive, partly because no studies include repeated measures prior to the onset of psychosis. In NAPLS2, we found that disrupted resting-state (rs) thalamo- cortical functional connectivity prior to psychosis predicts conversion and correlates with rate of GM decline, but we do not know if rs-dysconnectivity is progressive during the prodrome. Furthermore, in NAPLS2, plasma markers of pro-inflammatory cytokines at baseline predicted the rate of GM loss in converters; these same markers also correlated with rs-dysconnectivity. We do not yet know whether these inflammatory markers drive the changes in brain structure/function or are consequences of these changes. Similarly, higher levels of cortisol, and lower mismatch negativity predicted psychosis and the rate of PFC GM decline and were correlated with each other and with measures of rs-connectivity and cytokines. This application is a competitive renewal for a nine-site, longitudinal study aimed at identifying the brain processes underlying the progression of the clinical syndromes that characterize the psychosis prodrome. The goals are: 1) to determine the pre-onset trajectories of GM decline and disrupted resting-state brain connectivity in CHR individuals who develop psychosis using MRI, and 2) to identify inflammatory and plasticity mechanisms associated with transition to psychosis. Over a two-year period, the study will repeatedly measure these indicators, and at the same time examine changes in physiological indices of brain function, social and cognitive functioning, and symptom progression. The multi-site collaboration will follow large CHR (n= 378) and demographically matched comparison (n= 162) samples that will undergo comprehensive assessments of biological and behavioral changes. This approach will answer important questions about the origins of the brain changes that give rise to psychosis and will provide insights into likely approaches to halting or mitigatig the pathological process and advance our understanding of risk prediction, both critical steps in prevention.
 描述(由申请人提供):精神分裂症和其他精神障碍是严重且使人衰弱的精神疾病,会给患者带来巨大痛苦,并对我们的医疗保健系统造成重大挑战。临床高风险(CHR)前驱期是发病前的时期。当临床症状逐渐出现且功能衰退时,年轻人出现 CHR 综合征与后来发生精神病的哮喘风险(约 30%)相关。纵向研究 (NAPLS) 和其他 CHR 研究在预测精神病方面取得了实质性进展,并显示从精神病发作前到精神病发作后,CHR 转换器的前额皮质 (PFC) 灰质 (GM) 密度加速减少,但机制驱动转换仍然难以捉摸,部分原因是没有研究包括精神病发作前的重复测量。在 NAPLS2 中,我们发现精神病发生前的静息态 (rs) 丘脑皮质功能连接中断可以预测。转化并与 GM 下降率相关,但我们不知道在前驱症状期间 rs 连接断开是否是进展性的。此外,在 NAPLS2 中,基线时促炎细胞因子的血浆标记物预测了这些相同标记物的 GM 损失率。我们还不知道这些炎症标志物是否会导致大脑结构/功能的变化,或者是这些变化的结果。同样,较高水平的皮质醇和较低的失配消极性可以预测精神病和抑郁症。 PFC GM 下降率并相互关联,并与 rs 连接性和细胞因子的测量相关。该应用程序是一项九个站点的纵向研究的竞争性更新,旨在确定临床综合征进展的大脑过程。目标是:1) 使用 MRI 确定发生精神病的 CHR 个体中 GM 下降和静息态大脑连接中断的发病前轨迹,以及 2) 识别相关的炎症和可塑性机制。在两年的时间内,该研究将反复测量这些指标,同时检查大脑功能、社交和认知功能以及症状进展等生理指标的变化。大量 CHR (n= 378) 和人口统计匹配的比较 (n= 162) 样本将经历全面的生物学和行为变化,这种方法将回答有关引起精神病的大脑变化起源的重要问题,并将提供深入了解。可能的方法来停止或减轻病理过程并增进我们对风险预测的理解,这都是预防的关键步骤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott W Woods其他文献

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Acceleating Medicines Partnership® 精神分裂症 (AMP® SCZ):全球最大的精神病临床高风险前瞻性队列研究的基本原理和研究设计
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Cassandra M J Wannan;Barnaby Nelson;Jean Addington;K. Allott;A. Anticevic;Celso Arango;Justin T Baker;C. Bearden;Tashrif Billah;Sylvain Bouix;Matthew R Broome;Kate Buccilli;K. Cadenhead;Monica E. Calkins;T. Cannon;Guillermo Cecci;E. Y. Chen;Kang Ik K Cho;Jimmy Choi;Scott R. Clark;Michael J. Coleman;Philippe Conus;Cheryl M. Corcoran;B. Cornblatt;C. Díaz;Dominic Dwyer;B. Ebdrup;L. Ellman;Paolo Fusar‐Poli;Liliana Galindo;Pablo A. Gaspar;Carla Gerber;L. Glenthøj;Robert J Glynn;Michael P Harms;Leslie E Horton;René S. Kahn;J. Kambeitz;L. Kambeitz;John M Kane;Tina Kapur;M. Keshavan;Sung;N. Koutsouleris;M. Kubicki;J. Kwon;K. Langbein;K. Lewandowski;Gregory A. Light;D. Mamah;Patricia Marcy;D. Mathalon;Patrick D McGorry;V. A. Mittal;M. Nordentoft;Angela R. Nunez;O. Pasternak;Godfrey D Pearlson;Jesus Perez;D. Perkins;Albert R. Powers;D. Roalf;F. Sabb;Jason Schiffman;Jai L. Shah;S. Smesny;J. Spark;Wiliam S Stone;G. Strauss;Zailyn Tamayo;John Torous;R. Upthegrove;M. Vangel;Swapna Verma;Jijun Wang;I. Rossum;D. Wolf;Phillip Wolff;Stephen J. Wood;Alison R. Yung;Carla Agurto;M. Alvarez;P. Amminger;Marco Armando;Ameneh Asgari;John D Cahill;R. Carrión;Eduardo Castro;S. Cetin;M. Mallar Chakravarty;Youngsun T. Cho;David R Cotter;Simon D’Alfonso;M. Ennis;S. Fadnavis;C. Fonteneau;C. Gao;T. Gupta;Raquel E. Gur;Ruben C Gur;Holly K Hamilton;Gil D. Hoftman;Grace R Jacobs;Johanna M. Jarcho;J. L. Ji;Christian G. Kohler;P. Lalousis;S. Lavoie;Martin Lepage;Einat Liebenthal;Josh Mervis;Vishnu P. Murty;Spero C. Nicholas;Lipeng Ning;Nora Penzel;Russel Poldrack;Pablo Polosecki;Danielle N Pratt;Rachel Rabin;Habiballah Rahimi Eichi;Y. Rathi;Abraham Reichenberg;Jenna M. Reinen;Jack Rogers;Bernalyn Ruiz;Isabelle Scott;J. Seitz;Vinod H Srihari;Agrima Srivastava;Andrew Thompson;B. Turetsky;B. Walsh;T. Whitford;J. Wigman;Beier Yao;H. Yuen;Uzair Ahmed;A. Byun;Yoonho Chung;Kim Do;Larry Hendricks;Kevin Huynh;C. Jeffries;Erlend Lane;Carsten Langholm;Eric Lin;V. Mantua;Gennarina D Santorelli;K. Ruparel;Eirini Zoupou;Tatiana Adasme;Lauren Addamo;Laura L. Adery;Munaza Ali;A. Auther;Samantha Aversa;Seon;Kelly Bates;Alyssa Bathery;J. Bayer;Rebecca Beedham;Z. Bilgrami;Sonia Birch;I. Bonoldi;Owen Borders;Renato Borgatti;Lisa Brown;Alejandro Bruna;Holly Carrington;Rolando I Castillo;Justine Chen;Nicholas Cheng;Ann Ee Ching;Chloe Clifford;Beau;Pamela Contreras;Sebastián Corral;S. Damiani;Monica Done;A. Estradé;Brandon Asika Etuka;M. Formica;Rachel Furlan;Mia Geljic;Carmela Germano;Ruth Getachew;Mathias Goncalves;Anastasia Haidar;J. Hartmann;Anna Jo;Omar John;Sarah Kerins;M. Kerr;Irena Kesselring;Honey Kim;Nicholas Kim;Kyle S. Kinney;Marija Krcmar;Elana Kotler;Melanie Lafanechere;Clarice Lee;Joshua Llerena;C. Markiewicz;Priya Matnejl;Alejandro Maturana;Aissata Mavambu;Rocío Mayol;Amelia McDonnell;A. McGowan;Danielle McLaughlin;Rebecca McIlhenny;Brittany McQueen;Yohannes Mebrahtu;M. Mensi;C. Hui;Y. Suen;S. M. Wong;Neal Morrell;Mariam Omar;Alice Partridge;Christina Phassouliotis;A. Pichiecchio;P. Politi;Christian Porter;U. Provenzani;N. Prunier;Jasmine Raj;Susan Ray;Victoria Rayner;Manuel Reyes;Kate Reynolds;Sage Rush;César Salinas;J. Shetty;Callum Snowball;Sophie Tod;Gabriel Turra;Daniela Valle;Simone Veale;S. Whitson;Alana Wickham;Sarah Youn;Francisco Zamorano;Elissa Zavaglia;J. Zinberg;Scott W Woods;M. Shenton
  • 通讯作者:
    M. Shenton
Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study
减少未经治疗的精神病的持续时间及其对美国的影响:STEP-ED 研究
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    V. Srihari;C. Tek;J. Pollard;S. Zimmet;Jane Keat;J. Cahill;S. Kuçukgoncu;B. Walsh;Fangyong Li;R. Gueorguieva;Nina Levine;R. Mesholam;Michelle S. Friedman;Larry J. Seidman;M. Keshavan;T. Mcglashan;Scott W Woods
  • 通讯作者:
    Scott W Woods
The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis.
减轻精神病症状的复杂潜在结构:在临床精神病高风险的两个大样本中复制 SIPS 症状的分层和双因素模型。
  • DOI:
    10.1093/schbul/sbae042
  • 发表时间:
    2024-05-10
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    H. Cowan;Trevor F Williams;V. A. Mittal;Jean Addington;C. Bearden;K. Cadenhead;T. Cannon;B. Cornblatt;Matcheri Keshevan;D. Perkins;D. Mathalon;Wiliam S Stone;Scott W Woods;Elaine F Walker
  • 通讯作者:
    Elaine F Walker
Attenuated psychosis syndrome: ready for DSM-5.1?
减轻精神病综合征:准备好迎接 DSM-5.1 了吗?
  • DOI:
    10.1146/annurev-clinpsy-032813-153645
  • 发表时间:
    2014-03-28
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. Fusar;William T. Carpenter;Scott W Woods;T. McGlashan
  • 通讯作者:
    T. McGlashan
On the Proportion of Patients Who Experience a Prodrome Prior to Psychosis Onset - A Systematic Review and Meta-analysis
关于精神病发作前经历前驱症状的患者比例 - 系统回顾和荟萃分析
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    D. Benrimoh;Viktor Dlugunovych;A. Wright;P. Phalen;Melissa C Funaro;M. Ferrara;Albert R. Powers;Scott W Woods;Sinahin Guloksuz;A. Yung;V. Srihari;J. Shah
  • 通讯作者:
    J. Shah

Scott W Woods的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott W Woods', 18)}}的其他基金

8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    7849711
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
Huperzine for Cognitive and Functional Impairment in Schizophrenia
石杉碱甲治疗精神分裂症认知和功能障碍
  • 批准号:
    7538490
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    8066682
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/9 Predictors and Mechanisms of Conversion to Psychosis
8/9 转变为精神病的预测因素和机制
  • 批准号:
    8887584
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    7693812
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    8669445
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    8321221
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/9 Predictors and Mechanisms of Conversion to Psychosis
8/9 转变为精神病的预测因素和机制
  • 批准号:
    9054365
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
Huperzine for Cognitive and Functional Impairment in Schizophrenia
石杉碱甲治疗精神分裂症认知和功能障碍
  • 批准号:
    7694314
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:
8/8-Predictors and Mechanisms of Conversion to Psychosis
8/8-转变为精神病的预测因素和机制
  • 批准号:
    8793697
  • 财政年份:
    2008
  • 资助金额:
    $ 38.15万
  • 项目类别:

相似海外基金

Understanding how exocrine-derived signals promote beta cell growth
了解外分泌信号如何促进 β 细胞生长
  • 批准号:
    10750765
  • 财政年份:
    2024
  • 资助金额:
    $ 38.15万
  • 项目类别:
Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk) - Leadership Administrative Core (LAC)
提高女性高血压患者的意识:ROAR(农村、肥胖、危险)- 领导行政核心 (LAC)
  • 批准号:
    10714534
  • 财政年份:
    2023
  • 资助金额:
    $ 38.15万
  • 项目类别:
Characterizing the genetic etiology of delayed puberty with integrative genomic techniques
利用综合基因组技术表征青春期延迟的遗传病因
  • 批准号:
    10663605
  • 财政年份:
    2023
  • 资助金额:
    $ 38.15万
  • 项目类别:
A cloud-based digital health navigation program for colorectal cancer screening
基于云的结直肠癌筛查数字健康导航程序
  • 批准号:
    10697474
  • 财政年份:
    2023
  • 资助金额:
    $ 38.15万
  • 项目类别:
Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
  • 批准号:
    10643145
  • 财政年份:
    2023
  • 资助金额:
    $ 38.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了